Editing Pyritinol (section)

== Availability ==
It is approved for "symptomatic treatment of chronically impaired brain function in dementia syndromes" and for "supportive treatment of sequelae of craniocerebral trauma" in various European countries, including Austria, Germany, France, Italy, Portugal, and Greece. In France it is also approved for [[rheumatoid arthritis]] as a [[DMARD|disease modifying drug]], on the basis of the results of clinical trials. In many countries it is available over the counter and is widely advertised on the internet as being for "memory disturbances."{{citation needed|date=December 2019}}